Equities

Captor Therapeutics SA

Captor Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)74.00
  • Today's Change2.40 / 3.35%
  • Shares traded2.17k
  • 1 Year change-52.26%
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.

  • Revenue in PLN (TTM)16.16m
  • Net income in PLN-65.79m
  • Incorporated2018
  • Employees104.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Onesano SA12.34m-6.34m80.37m55.00--5.69--6.51-0.0962-0.09620.18730.21440.56491.416.78232,811.30-29.02-28.15-35.92--41.7550.87-51.38-29.922.77--0.0349--0.709328.40-61.92--101.90--
Sds Optic SA530.40k-7.39m116.96m----16.68--220.52-1.30-1.300.09281.190.054-5.912.11---75.38---94.39--167.64---1,395.87--4.85--0.00---99.59---85.26------
Urteste SA0.00-5.59m132.23m----4.77-----4.52-4.520.0019.680.003.86-----30.78---32.71----------17.11--0.0221---100.00---37.59------
Genomtec SA1.00k-9.01m139.25m----16.77--139,249.60-0.8037-0.80370.000090.67730.0000715.450.0008---65.01---80.98---81,000.00---901,300.00--2.11-46.670.1613---97.50--24.44------
Poltreg SA900.00k-15.65m214.52m23.00--2.55--238.35-3.36-3.360.19318.070.007343.393.2039,560.44-12.68-6.51-14.06-7.35-1,242.56-391.38-1,738.56-449.244.90--0.0868--40.04---588.92--214.26--
Molecure SA1.31m-18.31m256.24m111.00--1.63--195.82-1.17-1.170.08479.340.0085--0.281811,788.92-11.942.52-12.472.64-25.7697.54-1,398.8612.84----0.0434---18.85237.24-19.67---24.82--
Bioceltix SA0.00-12.73m265.52m----18.66-----3.45-3.450.003.450.00170.52-----112.58---140.07----------5.96--0.0071-------102.87------
Mabion SA146.11m42.34m284.46m226.006.722.105.721.952.622.629.048.370.70844.598.68646,495.6020.53-7.1928.38-16.7975.6658.1028.98-14.271.9325.960.1513---7.50--77.94--40.86--
BIOTON SA184.75m-2.63m302.24m358.00--0.50269.241.64-0.0306-0.03062.157.000.22911.006.74516,050.30-0.3261-1.99-0.3999-2.4734.7745.33-1.42-8.610.1841.160.0933---22.10-5.5160.10-38.690.3284--
Captor Therapeutics SA16.16m-65.79m316.53m104.00--5.83--19.58-15.07-15.073.6312.860.1741--5.14155,413.50-70.87---89.64--54.29---407.07------0.0458--44.15---96.65------
Synthaverse SA60.51m3.62m321.08m239.0095.403.0931.345.310.05160.05160.86051.590.26011.673.18253,192.501.563.531.834.3260.3955.625.989.590.87233.320.4038--16.3212.66-21.76--111.77--
Scope Fluidics SA93.00k-22.60m474.86m40.00--6.41--5,105.99-8.29-8.290.034127.180.00092.940.03372,325.00-21.7652.74-22.7457.32-2,022.58-420.87-24,304.3030,134.7813.86--0.0299--27.72---105.76--89.99--
Celon Pharma SA213.01m-28.31m796.48m568.00--1.8628.833.74-0.5545-0.55454.178.400.3641.827.08407,281.10-4.84-2.24-5.76-2.5771.0970.71-13.29-7.791.83--0.0546--11.2911.5728.40---13.42--
Data as of Jun 07 2024. Currency figures normalised to Captor Therapeutics SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

5.65%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 2023106.58k2.29%
Allianz Polska TFI SAas of 31 Dec 202393.91k2.02%
Millennium TFI SAas of 31 Dec 202328.20k0.61%
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 202312.42k0.27%
IPOPEMA TFI SAas of 31 Dec 202310.00k0.22%
Pekao TFI SAas of 30 Jun 20235.77k0.12%
Investors TFI SAas of 31 Dec 20225.65k0.12%
SSgA Funds Management, Inc.as of 09 May 202441.000.00%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.